Analyst Research

Report Title Price
Provider: Wright Reports
Provider: Reuters Investment Profile
Provider: GlobalData
Provider: GlobalData

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

ChronTech Pharma AB Announces Results of New Studies on IVIN Technology

Tuesday, 24 Sep 2013 01:40am EDT 

ChronTech Pharma AB announced that new studies have shown that the Company's IVIN technology is efficacious and that a better immune response is achievable using the same or even lower doses of DNA than when using a regular injection needle, irrespective of whether the injection is used in combination with in vivo electroporation or not. IVIN increases the number of vaccine specific T cells by more than 100% as compared to a regular needle when in combination with electroporation. Using IVIN strong immune responses can be achieved even when the dose is reduced 100-folds.